Sparebank 1 Ostfold Akershus (FOLD:NASDAQ)
$14.49 0.03 (0.2075%)
Analysed Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) News Sources
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
26-03-2026
yahoo.com
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
27-03-2026
yahoo.com
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
29-03-2026
yahoo.com
Here is Why BioMarin (BMRN) is Projected to Rally
31-03-2026
yahoo.com
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
25-04-2026
fool.com
BioMarin Completes Acquisition of Amicus Therapeutics
27-04-2026
yahoo.com
CIBRA Capital Buys Stake in Allied Gold Stock
27-04-2026
fool.com
BioMarin acquires Amicus Therapeutics for $4.8bn
28-04-2026
pharmaceutical-technology.com
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
05-05-2026
yahoo.com
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
05-05-2026
yahoo.com
What is the current price of Sparebank 1 Ostfold Akershus (FOLD:NASDAQ)?
The current price of Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) is $14.49.
Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) absolute price change since previous trading day?
The absolute price change of Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) since the previous trading day is $0.03.
Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) percentage price change since previous trading day?
The percentage price change of Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) since the previous trading day is 0.2075%.
What is the most recent average sentiment score for Sparebank 1 Ostfold Akershus (FOLD:NASDAQ)?
The most recent average sentiment score for Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for Sparebank 1 Ostfold Akershus (FOLD:NASDAQ)?
The most recent sentiment for Sparebank 1 Ostfold Akershus (FOLD:NASDAQ) is .
SEC-8K** Filing Available For Sparebank 1 Ostfold Akershus (FOLD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.